The Clorox Company $CLX Shares Sold by Birmingham Capital Management Co. Inc. AL

Birmingham Capital Management Co. Inc. AL decreased its holdings in shares of The Clorox Company (NYSE:CLX) by 7.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,391 shares of the company’s stock after selling 611 shares during the period. Birmingham Capital Management Co. Inc. AL’s holdings in Clorox were worth $1,088,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Strs Ohio purchased a new position in Clorox during the 1st quarter valued at about $1,537,000. Geneos Wealth Management Inc. lifted its stake in Clorox by 70.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 2,652 shares of the company’s stock valued at $391,000 after buying an additional 1,094 shares in the last quarter. Belpointe Asset Management LLC grew its holdings in Clorox by 6.9% during the 1st quarter. Belpointe Asset Management LLC now owns 3,181 shares of the company’s stock valued at $469,000 after buying an additional 206 shares during the last quarter. Intech Investment Management LLC increased its position in Clorox by 25.4% during the first quarter. Intech Investment Management LLC now owns 68,261 shares of the company’s stock worth $10,051,000 after buying an additional 13,833 shares in the last quarter. Finally, Focus Partners Wealth increased its position in Clorox by 34.4% during the first quarter. Focus Partners Wealth now owns 14,936 shares of the company’s stock worth $2,199,000 after buying an additional 3,824 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CLX. Wells Fargo & Company decreased their price objective on Clorox from $138.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Friday, September 5th. Jefferies Financial Group reduced their target price on shares of Clorox from $167.00 to $145.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Barclays lowered their price target on shares of Clorox from $129.00 to $119.00 and set an “underweight” rating for the company in a report on Tuesday, July 15th. JPMorgan Chase & Co. boosted their price objective on shares of Clorox from $133.00 to $135.00 and gave the company a “neutral” rating in a research report on Monday. Finally, UBS Group decreased their target price on shares of Clorox from $150.00 to $134.00 and set a “neutral” rating on the stock in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Clorox has a consensus rating of “Reduce” and an average price target of $142.18.

Insider Transactions at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total value of $1,861,774.98. Following the transaction, the chief operating officer owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.57% of the company’s stock.

Clorox Price Performance

CLX opened at $123.35 on Thursday. The Clorox Company has a 1 year low of $116.53 and a 1 year high of $171.37. The company’s 50 day simple moving average is $124.30 and its 200 day simple moving average is $132.88. The stock has a market capitalization of $15.09 billion, a PE ratio of 18.92, a P/E/G ratio of 1.01 and a beta of 0.52. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter last year, the firm posted $1.82 earnings per share. Clorox’s revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, sell-side analysts expect that The Clorox Company will post 7.15 EPS for the current year.

Clorox Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 29th. Shareholders of record on Wednesday, August 13th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 4.0%. This is a boost from Clorox’s previous quarterly dividend of $1.22. The ex-dividend date of this dividend was Wednesday, August 13th. Clorox’s dividend payout ratio (DPR) is presently 76.07%.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.